Disc
Watertown, Massachusetts, United States · Biopharma, Biotechnology, Health Care
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
Key facts
- Headquarters
- Watertown, Massachusetts, United States
- Employees
- 174
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- discmedicine.com
- Company page
Recent activity at Disc
- : Disc Medicine Raises $422.4 Million in Public Offering
- : Disc Medicine, Inc. showcases clinical and translational data at ASH 2024 annual meeting in San Diego.
- : Disc Medicine Secures $200 Million Non-Dilutive Debt Financing from Hercules Capital, Inc.
- : Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
- : Disc Medicine Announces $62.5 Million Financing Led By Bain Capital Life Sciences To Advance Portfolio Of Novel Hematology Programs
- : Disc Medicine Announces $90 Million Series B Financing To Advance Portfolio Of Clinical-Stage Therapies For Hematologic Diseases
Disc funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Post-IPO Equity | $422.4M |
| Feb 2023 | Funding Round | $62.5M |
| Sep 2021 | Series B | $90.0M |
Leadership
- Pamela Stephenson, Chief Commercial Officer
Verified email and direct lines for Disc’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Disc files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Disc in the news
- Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study - Yahoo Finance (Oct 22, 2026)
- Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP - Dermatology Times (Oct 19, 2026)
- Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) - Carroll County Mirror-Democrat (Oct 19, 2026)
- Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) - The Manila Times (Oct 18, 2026)
- A drug's late-stage trial results will be discussed Monday. - Stock Titan (Oct 18, 2026)
- Disc Medicine to Host Webcast on APOLLO Phase 3 Topline Results for Bitopertin in EPP - Quiver Quantitative (Oct 18, 2026)
- Disc Medicine: The CRL Has Created A Cleaner Bull Case (NASDAQ:IRON) - Seeking Alpha (Jun 17, 2026)
- FDA Issues CRL to Disc Medicine for Eythropoietic Protoporphyria Treatment Bitopertin - Pharmaceutical Executive (Feb 16, 2026)
Companies similar to Disc
- TerSera · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Parabilis Medicines · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Supernus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Aurinia Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Avadel · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Disc: questions and answers
What does Disc do?
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
Where is Disc headquartered?
Disc is headquartered in Watertown, Massachusetts, United States.
How many employees does Disc have?
Disc has about 174 employees.
Has Disc raised funding?
Yes. Fundz has recorded 3 funding events for Disc. The most recent, Post-IPO Equity of $422.4M, was in Oct 2026.
What is the latest news on Disc?
On Oct 20, 2026, Disc Medicine Raises $422.4 Million in Public Offering
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy